Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release
Modified vaccinia virus Ankara (MVA) is an attenuated strain derived from vaccinia virus (VV) Ankara that grows efficiently in primary chicken embryo fibroblasts (CEFs) and baby hamster kidney cells only. MVA produces significantly more of the enveloped forms of VV in infected CEFs compared with VV strain Copenhagen. In the present study, production of the different infectious forms of VV was compared in CEFs infected with MVA or with two well-characterized replication-competent VV strains, WR and IHD-J. In a time-course experiment, the infectivity associated with the extracellular enveloped virus (EEV), the cell-associated enveloped virus (CEV) and intracellular mature and enveloped viruses was determined. Further, the production of the different viral forms was quantified by electron microscopy (EM). The data collectively indicate that IHD-J is most efficient in producing all of the trans-Golgi network-wrapped forms and releases the highest titres of EEVs into the extracellular medium, with WR being least efficient. MVA initially replicated with faster kinetics, resulting in more intracellular virus and CEVs between 8 and 24 h post-infection (p.i.). As assessed by EM, the faster growth kinetics of MVA resulted in 3·5-fold more CEVs at the cell surface at 24 h p.i., compared with both WR and IHD-J. Accordingly, we found that despite the presence of two in-frame deletions in the A36R gene of MVA, this virus was able to make actin tails in CEFs.
AntoineG.,
ScheiflingerF.,
DornerF.,
FalknerF. G.1998; The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365–396
BelyakovI. M.,
WyattL. S.,
AhlersJ. D.,
EarlP.,
PendletonD.,
KelsallB. L.,
StroberW.,
MossB.,
BerzofskyJ. A.1998; Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 72:8264–8272
BlascoR.,
MossB.1991; Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by a deletion of the gene encoding the 37,000-dalton outer envelope protein. J Virol 65:5910–5920
BlascoR.,
SislerJ. R.,
MossB.1993; Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J Virol 67:3319–3325
CarrollM. W.,
MossB.1997; Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198–211
CarrollM. W.,
OverwijkW. W.,
CharmberlainR. S.,
RosenbergS. A.,
MossB.,
RestifoN. P.1997; Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15:387–394
DrexlerI.,
HellerK.,
WahrenB.,
ErfleV.,
SutterG.1998; Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79:347–352
DrexlerI.,
AntunesE.,
SchmitzM.,
WoelfelT.,
HuberC.,
ErfleV.,
RieberP.,
TheobaldM.,
SutterG.1999; Modified virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 59:4955–4963
EarlP. L.,
CooperN.,
WyattL. S.,
MossB.,
CarrollM. W.1998; Titration of MVA stocks by immunostaining. In Current Protocols In Molecular Biology pp. 16.16.9–16.16.11 Edited by
AusubelF. M.,
KingstonR. E.,
MooreD. D.,
SeidmanJ. G.,
SmithJ. A.,
StruhlK.
New York: Greene/Wiley Interscience;
HirschV. M.,
FuerstT. R.,
SutterG.9 other authors1996; Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741–3752
HollinsheadM.,
RodgerG.,
Van EijlH.,
LawM.,
HollinsheadR.,
VauxD. J. T.,
SmithG. L.2001; Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol 154:389–402
KatzE.,
MossB.1997; Immunogenicity of recombinant vaccinia viruses that display the HIV type I envelope glycoprotein on the surface of infectious virions. AIDS Res 13:1497–1500
KatzE.,
WolffeE. J.,
MossB.1997; The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type I glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 71:3178–3187
MayrA.,
SticklH.,
MüllerH. K.,
DannerK.,
SingerH.1978; Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwächten Organismus. Zentbl Bakteriol Hyg, I, Abt Orig B 167:375–390
PayneL. G.1979; Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J Virol 31:147–155
SanchoM. C.,
SchleichS.,
GriffithsG.,
Krijnse LockerJ.2002; The block in morphogenesis of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus assembly. J Virol 76:8318–8334
SchmelzM.,
SodeikB.,
EricssonM.,
WolffeE.,
ShidaH.,
HillerG.,
GriffithsG.1994; Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 68:130–147
SchneiderJ.,
GilbertS. C.,
BlanchardT. J.7 other authors1998; Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4:397–402
SodeikB.,
Krijnse LockerJ.2002; Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host?. Trends Microbiol 10:15–24
SpehnerD.,
DrillienR.,
ProamerF.,
Houssais-PêcheurC.,
ZantaM.-A.,
GeistM.,
DottK.,
BalloulJ.-M.2000; Enveloped virus is the major virus form produced during productive infection with modified vaccinia virus Ankara strain. Virology 273:9–15
SutterG.,
WyattL. S.,
FoleyP. L.,
BenninkJ. R.,
MossB.1994; A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032–1040
UlaetoD.,
GrosenbachD.,
HrubyD. E.1995; Brefeldin A inhibits vaccinia virus envelopment but does not prevent normal processing and localization of the putative envelopment receptor P37. J Gen Virol 76:103–111
van der MeerY.,
SnijderE. J.,
DobbeJ. C.,
SchleichS.,
DenisonM. R.,
SpaanW. J. M.,
Krijnse LockerJ.1999; The localization of mouse hepatitis virus nonstructural proteins and RNA synthesis indicates a role for late endosomes in viral replication. J Virol 73:7641–7657
van EijlH.,
HollinsheadM.,
RodgerG.,
ZhangW. H.,
SmithG. L.2002; The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. J Gen Virol 83:195–207
WardB. M.,
MossB.2001; Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein–B5R membrane protein chimera. J Virol 75:4802–4813
Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release